vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and SERVICE CORP INTERNATIONAL (SCI). Click either name above to swap in a different company.
SERVICE CORP INTERNATIONAL is the larger business by last-quarter revenue ($1.1B vs $708.5M, roughly 1.6× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 14.3%, a 4.7% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 1.7%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $87.2M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 3.1%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
International Distribution Services Limited is a British company providing postal and courier services. IDS was created in 2013 by the UK government as a new holding company of Royal Mail, and a majority of its shares were then sold on the London Stock Exchange, with the government initially retaining a 30 per cent at the time. As of April 2025, IDS is owned and operated by Czech-based EP Group, owned by Daniel Křetínský.
MEDP vs SCI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $1.1B |
| Net Profit | $135.1M | $159.4M |
| Gross Margin | — | 28.0% |
| Operating Margin | 21.6% | 24.8% |
| Net Margin | 19.1% | 14.3% |
| Revenue YoY | 32.0% | 1.7% |
| Net Profit YoY | 15.5% | 5.3% |
| EPS (diluted) | $4.65 | $1.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $708.5M | $1.1B | ||
| Q3 25 | $659.9M | $1.1B | ||
| Q2 25 | $603.3M | $1.1B | ||
| Q1 25 | $558.6M | $1.1B | ||
| Q4 24 | $536.6M | $1.1B | ||
| Q3 24 | $533.3M | $1.0B | ||
| Q2 24 | $528.1M | $1.0B | ||
| Q1 24 | $511.0M | $1.0B |
| Q4 25 | $135.1M | $159.4M | ||
| Q3 25 | $111.1M | $117.5M | ||
| Q2 25 | $90.3M | $122.9M | ||
| Q1 25 | $114.6M | $142.9M | ||
| Q4 24 | $117.0M | $151.4M | ||
| Q3 24 | $96.4M | $117.8M | ||
| Q2 24 | $88.4M | $118.2M | ||
| Q1 24 | $102.6M | $131.3M |
| Q4 25 | — | 28.0% | ||
| Q3 25 | — | 25.1% | ||
| Q2 25 | — | 25.5% | ||
| Q1 25 | — | 27.1% | ||
| Q4 24 | — | 28.0% | ||
| Q3 24 | — | 24.9% | ||
| Q2 24 | — | 24.9% | ||
| Q1 24 | — | 26.2% |
| Q4 25 | 21.6% | 24.8% | ||
| Q3 25 | 21.5% | 21.4% | ||
| Q2 25 | 20.9% | 21.1% | ||
| Q1 25 | 20.3% | 23.4% | ||
| Q4 24 | 23.4% | 24.0% | ||
| Q3 24 | 21.1% | 20.9% | ||
| Q2 24 | 19.9% | 21.4% | ||
| Q1 24 | 20.4% | 22.2% |
| Q4 25 | 19.1% | 14.3% | ||
| Q3 25 | 16.8% | 11.1% | ||
| Q2 25 | 15.0% | 11.5% | ||
| Q1 25 | 20.5% | 13.3% | ||
| Q4 24 | 21.8% | 13.8% | ||
| Q3 24 | 18.1% | 11.6% | ||
| Q2 24 | 16.7% | 11.4% | ||
| Q1 24 | 20.1% | 12.6% |
| Q4 25 | $4.65 | $1.13 | ||
| Q3 25 | $3.86 | $0.83 | ||
| Q2 25 | $3.10 | $0.86 | ||
| Q1 25 | $3.67 | $0.98 | ||
| Q4 24 | $3.67 | $1.02 | ||
| Q3 24 | $3.01 | $0.81 | ||
| Q2 24 | $2.75 | $0.81 | ||
| Q1 24 | $3.20 | $0.89 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | $243.6M |
| Total DebtLower is stronger | — | $5.1B |
| Stockholders' EquityBook value | $459.1M | $1.6B |
| Total Assets | $2.0B | $18.7B |
| Debt / EquityLower = less leverage | — | 3.10× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $497.0M | $243.6M | ||
| Q3 25 | $285.4M | $241.3M | ||
| Q2 25 | $46.3M | $255.4M | ||
| Q1 25 | $441.4M | $227.2M | ||
| Q4 24 | $669.4M | $218.8M | ||
| Q3 24 | $656.9M | $185.4M | ||
| Q2 24 | $510.9M | $184.4M | ||
| Q1 24 | $407.0M | $205.6M |
| Q4 25 | — | $5.1B | ||
| Q3 25 | — | $5.0B | ||
| Q2 25 | — | $5.0B | ||
| Q1 25 | — | $4.7B | ||
| Q4 24 | — | $4.8B | ||
| Q3 24 | — | $4.7B | ||
| Q2 24 | — | $4.7B | ||
| Q1 24 | — | $4.6B |
| Q4 25 | $459.1M | $1.6B | ||
| Q3 25 | $293.6M | $1.6B | ||
| Q2 25 | $172.4M | $1.6B | ||
| Q1 25 | $593.6M | $1.7B | ||
| Q4 24 | $825.5M | $1.7B | ||
| Q3 24 | $881.4M | $1.6B | ||
| Q2 24 | $763.6M | $1.5B | ||
| Q1 24 | $671.5M | $1.6B |
| Q4 25 | $2.0B | $18.7B | ||
| Q3 25 | $1.8B | $18.4B | ||
| Q2 25 | $1.6B | $18.0B | ||
| Q1 25 | $1.9B | $17.3B | ||
| Q4 24 | $2.1B | $17.4B | ||
| Q3 24 | $2.1B | $17.4B | ||
| Q2 24 | $1.9B | $16.8B | ||
| Q1 24 | $1.8B | $16.7B |
| Q4 25 | — | 3.10× | ||
| Q3 25 | — | 3.17× | ||
| Q2 25 | — | 3.19× | ||
| Q1 25 | — | 2.87× | ||
| Q4 24 | — | 2.83× | ||
| Q3 24 | — | 2.92× | ||
| Q2 24 | — | 3.05× | ||
| Q1 24 | — | 2.90× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | $212.9M |
| Free Cash FlowOCF − Capex | $188.1M | $87.2M |
| FCF MarginFCF / Revenue | 26.6% | 7.8% |
| Capex IntensityCapex / Revenue | 0.6% | 11.3% |
| Cash ConversionOCF / Net Profit | 1.43× | 1.34× |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | $554.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $192.7M | $212.9M | ||
| Q3 25 | $246.2M | $252.3M | ||
| Q2 25 | $148.5M | $166.4M | ||
| Q1 25 | $125.8M | $311.1M | ||
| Q4 24 | $190.7M | $264.1M | ||
| Q3 24 | $149.1M | $263.8M | ||
| Q2 24 | $116.4M | $196.9M | ||
| Q1 24 | $152.7M | $220.1M |
| Q4 25 | $188.1M | $87.2M | ||
| Q3 25 | $235.5M | $150.7M | ||
| Q2 25 | $142.4M | $83.4M | ||
| Q1 25 | $115.8M | $233.0M | ||
| Q4 24 | $183.0M | $151.8M | ||
| Q3 24 | $138.5M | $162.8M | ||
| Q2 24 | $103.5M | $100.8M | ||
| Q1 24 | $147.2M | $140.3M |
| Q4 25 | 26.6% | 7.8% | ||
| Q3 25 | 35.7% | 14.2% | ||
| Q2 25 | 23.6% | 7.8% | ||
| Q1 25 | 20.7% | 21.7% | ||
| Q4 24 | 34.1% | 13.9% | ||
| Q3 24 | 26.0% | 16.1% | ||
| Q2 24 | 19.6% | 9.7% | ||
| Q1 24 | 28.8% | 13.4% |
| Q4 25 | 0.6% | 11.3% | ||
| Q3 25 | 1.6% | 9.6% | ||
| Q2 25 | 1.0% | 7.8% | ||
| Q1 25 | 1.8% | 7.3% | ||
| Q4 24 | 1.4% | 10.3% | ||
| Q3 24 | 2.0% | 10.0% | ||
| Q2 24 | 2.4% | 9.3% | ||
| Q1 24 | 1.1% | 7.6% |
| Q4 25 | 1.43× | 1.34× | ||
| Q3 25 | 2.22× | 2.15× | ||
| Q2 25 | 1.65× | 1.35× | ||
| Q1 25 | 1.10× | 2.18× | ||
| Q4 24 | 1.63× | 1.75× | ||
| Q3 24 | 1.55× | 2.24× | ||
| Q2 24 | 1.32× | 1.67× | ||
| Q1 24 | 1.49× | 1.68× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
SCI
| Cemetery | $510.9M | 46% |
| Funeral Matured Preneed Revenue | $196.5M | 18% |
| Cemetery Recognized Preneed Merchandise And Service Revenue | $107.4M | 10% |
| Cemetery Atneed Revenue | $104.9M | 9% |
| CA | $56.4M | 5% |
| Funeral Other Revenue | $54.6M | 5% |
| Cemetery Other Revenue | $40.2M | 4% |
| Nonfuneral Home Revenue | $28.1M | 3% |
| Non Funeral Home Preneed Sales Revenue | $22.0M | 2% |
